June 20th 2025
Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.
Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.
Proteasome Inhibitors Show Promise as Treatment for Multiple Myeloma